VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR ROVADICITINIB WITH SANOFI

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2026

VOLUNTARY ANNOUNCEMENT - “ROVADICITINIB TABLET” APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF BENMELSTOBART INJECTION FOR THE INDICATION OF MAINTENANCE THERAPY AFTER CHEMORADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER

VOLUNTARY ANNOUNCEMENT - COMPLETION OF SUBJECT ENROLLMENT IN PHASE III CLINICAL TRIAL OF TQB2102 “HER2 BISPECIFIC ADC” FOR HER2-LOW BREAST CANCER

VOLUNTARY ANNOUNCEMENT - COMPLETION OF SUBJECT ENROLLMENT IN PHASE III CLINICAL TRIAL OF TECOTABART VEDOTIN “CLDN18.2 ADC”

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2026

VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE II TRIAL OF TQA3605 "CORE PROTEIN ALLOSTERIC MODULATOR" FOR CHRONIC HEPATITIS B